Neurobiology of Aging
Volume 29, Issue 10 , Pages 1524-1532 , October 2008

Alterations in NMDA receptor subunit densities and ligand binding to glycine recognition sites are associated with chronic anxiety in Alzheimer's disease

  • Shirley W.Y. Tsang

      Affiliations

    • Dementia Research Laboratory, Department of Clinical Research, Singapore General Hospital, Singapore
    • ,
  • Harry V. Vinters

      Affiliations

    • Department of Pathology & Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
    • Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
    • ,
  • Jeffrey L. Cummings

      Affiliations

    • Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
    • ,
  • Peter T.-H. Wong

      Affiliations

    • Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore
    • ,
  • Christopher P.L.-H. Chen

      Affiliations

    • Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore
    • ,
  • Mitchell K.P. Lai

      Affiliations

    • Dementia Research Laboratory, Department of Clinical Research, Singapore General Hospital, Singapore
    • Corresponding Author InformationCorresponding author at: Dementia Research Laboratory, Department of Clinical Research, Block 6, Level 6, Room B22, Singapore General Hospital, Outram Road, 169608 Singapore, Singapore. Tel.: +65 6326 6384; fax: +65 6225 7796.

Received 3 November 2006 ,Revised 18 February 2007 ,Accepted 8 March 2007.

References 

  1. Anthony EW, Nevins ME. Anxiolytic-like effects of N-methyl-d-aspartate-associated glycine receptor ligands in the rat potentiated startle test. Eur. J. Pharmacol. 1993;250:317–324
  2. Baron BM, Harrison BL, Kehne JH, Schmidt CJ, van Giersbergen PL, White HS, et al. Pharmacological characterization of MDL 105,519, an NMDA receptor glycine site antagonist. Eur. J. Pharmacol. 1997;323:181–192
  3. Bi H, Sze CI. N-Methyl-aspartate receptor subunit NR2A and NR2B messenger RNA levels are altered in the hippocampus and entorhinal cortex in Alzheimer's disease. J. Neurol. Sci. 2002;200:11–18
  4. Boyce-Rustay JM, Holmes A. Genetic inactivation of the NMDA receptor NR2A subunit has anxiolytic- and anti-depressant-like effects in mice. Neuropsychopharmacology. 2006;31:2405–2414
  5. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. (Berl.). 1991;82:239–259
  6. Chen CP, Alder JT, Bowen DM, Esiri MM, McDonald B, Hope T, et al. Presynaptic serotonergic markers in community-acquired cases of Alzheimer's disease: correlations with depression and neuroleptic medication. J. Neurochem. 1996;66:1592–1598
  7. Chen HS, Lipton SA. The chemical biology of clinically tolerated NMDA receptor antagonists. J. Neurochem. 2006;97:1611–1626
  8. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44:2308–2314
  9. Danysz W, Parsons CG, Bresink I, Quack G. Glutamate in CNS disorders. Drug News Perspect. 1996;8:261–277
  10. Dingledine R, Borges K, Bowie D, Traynelis SF. The glutamate receptor ion channels. Pharmacol. Rev. 1999;51:7–62
  11. Folstein MF, Folstein SE, McHugh PR. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 1975;12:189–198
  12. Francis PT. Glutamatergic systems in Alzheimer's disease. Int. J. Geriatr. Psychiat. 2003;18(Suppl. 1):S15–S21
  13. Francis PT, Sims NR, Procter AW, Bowen DM. Cortical pyramidal neurone loss may cause glutamatergic hypoactivity and cognitive impairment in Alzheimer's disease: investigative and therapeutic perspectives. J. Neurochem. 1993;60:1589–1604
  14. Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's disease Cooperative Study. Alzheimer Dis. Assoc. Disord. 1997;11(Suppl. 2):S33–S39
  15. Gilley DW, Bienias JL, Wilson RS, Bennett DA, Beck TL, Evans DA. Influence of behavioral symptoms on rates of institutionalization for persons with Alzheimer's disease. Psychol. Med. 2004;34:1129–1135
  16. Hirai H, Kirsch J, Laube B, Betz H, Kuhse J. The glycine binding site of the N-methyl-d-aspartate receptor subunit NR1: identification of novel determinants of co-agonist potentiation in the extracellular M3–M4 loop region. Proc. Natl. Acad. Sci. U.S.A. 1996;93:6031–6036
  17. Hollmann M, Heinemann S. Cloned glutamate receptors. Annu. Rev. Neurosci. 1994;17:31–108
  18. Hope T, Keene J, Fairburn CG, Jacoby R, McShane R. Natural history of behavioural changes and psychiatric symptoms in Alzheimer's disease. A longitudinal study. Br. J. Psychiatry. 1999;174:39–44
  19. Hoyer S, Nitsch R. Cerebral excess release of neurotransmitter amino acids subsequent to reduced cerebral glucose metabolism in early-onset dementia of Alzheimer type. J. Neural Transm. 1989;75:227–232
  20. Huh KH, Wenthold RJ. Turnover analysis of glutamate receptors identifies a rapidly degraded pool of the N-methyl-d-aspartate receptor subunit, NR1, in cultured cerebellar granule cells. J. Biol. Chem. 1999;274:151–157
  21. Hynd MR, Scott HL, Dodd PR. Differential expression of N-methyl-d-aspartate receptor NR2 isoforms in Alzheimer's disease. J. Neurochem. 2004;90:913–919
  22. Hynd MR, Scott HL, Dodd PR. Selective loss of NMDA receptor NR1 subunit isoforms in Alzheimer's disease. J. Neurochem. 2004;89:240–247
  23. IPA, 1996. Behavioral and psychological signs and symptoms of dementia: implications for research and treatment. Proceedings of An International Consensus Conference, Lansdowne, Virginia, April 1996. Int. Psychogeriatr 8 (Suppl. 3) (1996) 215–552.
  24. Itokawa M, Yamada K, Yoshitsugu K, Toyota T, Suga T, Ohba H, et al. A microsatellite repeat in the promoter of the N-methyl-d-aspartate receptor 2A subunit (GRIN2A) gene suppresses transcriptional activity and correlates with chronic outcome in schizophrenia. Pharmacogenetics. 2003;13:271–278
  25. Kutsuwada T, Kashiwabuchi N, Mori H, Sakimura K, Kushiya E, Araki K, et al. Molecular diversity of the NMDA receptor channel. Nature. 1992;358:36–41
  26. Lai MK, Lai OF, Keene J, Esiri MM, Francis PT, Hope T, et al. Psychosis of Alzheimer's disease is associated with elevated muscarinic M2 binding in the cortex. Neurology. 2001;57:805–811
  27. Lai MK, Tsang SW, Francis PT, Esiri MM, Keene J, Hope T, et al. Reduced serotonin 5-HT1A receptor binding in the temporal cortex correlates with aggressive behavior in Alzheimer disease. Brain Res. 2003;974:82–87
  28. Laurie DJ, Seeburg PH. Ligand affinities at recombinant N-methyl-d-aspartate receptors depend on subunit composition. Eur. J. Pharmacol. 1994;268:335–345
  29. Leeson PD, Iversen LL. The glycine site on the NMDA receptor: structure–activity relationships and therapeutic potential. J. Med. Chem. 1994;37:4053–4067
  30. Li Z, Becker J, Noe CR. Functional expression of recombinant N-methyl-d-aspartate receptors in the yeast Saccharomyces cerevisiae—localization and pharmacological characterization. Eur. J. Biochem. 1998;252(3):391–399
  31. Matthews KL, Chen CP, Esiri MM, Keene J, Minger SL, Francis PT. Noradrenergic changes, aggressive behavior, and cognition in patients with dementia. Biol. Psychiatry. 2002;51:407–416
  32. Mayer ML, Westbrook GL, Guthrie PB. Voltage-dependent block by Mg2+ of NMDA responses in spinal cord neurones. Nature. 1984;309:261–263
  33. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939–944
  34. McPherson GA. Analysis of radioligand binding experiments. A collection of computer programs for the IBM PC. J. Pharmacol. Methods. 1985;14:213–228
  35. Mega MS, Cummings JL, Fiorello T, Gornbein J. The spectrum of behavioral changes in Alzheimer's disease. Neurology. 1996;46:130–135
  36. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, et al. The Consortium to Establish a Registry for Alzheimer's disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 1991;41:479–486
  37. Mitchell JJ, Anderson KJ. Age-related changes in [3H]MK-801 binding in the Fischer 344 rat brain. Neurobiol. Aging. 1998;19:259–265
  38. Mu Y, Otsuka T, Horton AC, Scott DB, Ehlers MD. Activity-dependent mRNA splicing controls ER export and synaptic delivery of NMDA receptors. Neuron. 2003;40:581–594
  39. Newcomer JW, Krystal JH. NMDA receptor regulation of memory and behavior in humans. Hippocampus. 2001;11:529–542
  40. Olney JW, Newcomer JW, Farber NB. NMDA receptor hypofunction model of schizophrenia. J. Psychiatr. Res. 1999;33:523–533
  41. Priestley T, Laughton P, Myers J, Le BB, Kerby J, Whiting PJ. Pharmacological properties of recombinant human N-methyl-d-aspartate receptors comprising NR1a/NR2A and NR1a/NR2B subunit assemblies expressed in permanently transfected mouse fibroblast cells. Mol. Pharmacol. 1995;48:841–848
  42. Procter AW, Stirling JM, Stratmann GC, Cross AJ, Bowen DM. Loss of glycine-dependent radioligand binding to the N-methyl-d-aspartate-phencyclidine receptor complex in patients with Alzheimer's disease. Neurosci. Lett. 1989;101:62–66
  43. Procter AW, Wong EH, Stratmann GC, Lowe SL, Bowen DM. Reduced glycine stimulation of [3H]MK-801 binding in Alzheimer's disease. J. Neurochem. 1989;53:698–704
  44. Riedel G, Platt B, Micheau J. Glutamate receptor function in learning and memory. Behav. Brain Res. 2003;140:1–47
  45. Schmitt ML, Coelho W, Lopes-de-Souza AS, Guimaraes FS, Carobrez AP. Anxiogenic-like effect of glycine and d-serine microinjected into dorsal periaqueductal gray matter of rats. Neurosci. Lett. 1995;189:93–96
  46. Simon AB, Gorman JM. Advances in the treatment of anxiety: targeting glutamate. NeuroRx. 2006;3:57–68
  47. Smith CC, Bowen DM, Sims NR, Neary D, Davison AN. Amino acid release from biopsy samples of temporal neocortex from patients with Alzheimer's disease. Brain Res. 1983;264:138–141
  48. Smith KE, Borden LA, Hartig PR, Branchek T, Weinshank RL. Cloning and expression of a glycine transporter reveal colocalization with NMDA receptors. Neuron. 1992;8:927–935
  49. Standley S, Roche KW, McCallum J, Sans N, Wenthold RJ. PDZ domain suppression of an ER retention signal in NMDA receptor NR1 splice variants. Neuron. 2000;28(3):887–898
  50. Suen PC, Wu K, Xu JL, Lin SY, Levine ES, Black IB. NMDA receptor subunits in the postsynaptic density of rat brain: expression and phosphorylation by endogenous protein kinases. Mol. Brain Res. 1998;59:215–228
  51. Sze C, Bi H, Kleinschmidt-DeMasters BK, Filley CM, Martin LJ. N-Methyl-d-aspartate receptor subunit proteins and their phosphorylation status are altered selectively in Alzheimer's disease. J. Neurol. Sci. 2001;182:151–159
  52. Tanaka Y, Meguro K, Yamaguchi S, Ishii H, Watanuki S, Funaki Y, et al. Decreased striatal D2 receptor density associated with severe behavioral abnormality in Alzheimer's disease. Ann. Nucl. Med. 2003;17:567–573
  53. Tekin S, Mega MS, Masterman DM, Chow T, Garakian J, Vinters HV, et al. Orbitofrontal and anterior cingulate cortex neurofibrillary tangle burden is associated with agitation in Alzheimer disease. Ann. Neurol. 2001;49:355–361
  54. Thomson AM. Glycine is a co-agonist at the NMDA receptor/channel complex. Prog. Neurobiol. 1990;35:53–74
  55. Tsang SW, Pomakian J, Marshall GA, Vinters HV, Cummings JL, Chen CP, et al. Disrupted muscarinic M1 receptor signaling correlates with loss of protein kinase C activity and glutamatergic deficit in Alzheimer's disease. Neurobiol. Aging. 2007;28:1381–1387
  56. Van Hoesen GW, Parvizi J, Chu CC. Orbitofrontal cortex pathology in Alzheimer's disease. Cereb. Cortex. 2000;10:243–251
  57. Wafford KA, Kathoria M, Bain CJ, Marshall G, Le BB, Kemp JA, et al. Identification of amino acids in the N-methyl-d-aspartate receptor NR1 subunit that contribute to the glycine binding site. Mol. Pharmacol. 1995;47:374–380
  58. Wenzel A, Scheurer L, Kunzi R, Fritschy JM, Mohler H, Benke D. Distribution of NMDA receptor subunit proteins NR2A, 2B, 2C and 2D in rat brain. Neuroreport. 1995;7:45–48
  59. Wong EH, Knight AR, Woodruff GN. [3H]MK-801 labels a site on the N-methyl-d-aspartate receptor channel complex in rat brain membranes. J. Neurochem. 1988;50:274–281
  60. Wynn ZJ, Cummings JL. Cholinesterase inhibitor therapies and neuropsychiatric manifestations of Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 2004;17:100–108
  61. Zukin RS, Bennett MV. Alternatively spliced isoforms of the NMDARI receptor subunit. Trends Neurosci. 1995;18:306–313

PII: S0197-4580(07)00122-4

doi: 10.1016/j.neurobiolaging.2007.03.014

Neurobiology of Aging
Volume 29, Issue 10 , Pages 1524-1532 , October 2008

Article Tools

* Image Usage & Resolution